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The clinical specialty of nephrology spans
from the basic clinical skills through to
highly technological aspects of medicine.
The areas of technology reviewed in this
article pertain to dialysis therapies for
both acute and chronic renal failure. Pre-
dialysis care and prevention or delay of
progression are not covered.
In the 19th century Graham described the
physicochemical process of dialysis. In the
early part of the 20th century laboratory
attempts at dialysis were made, but suc-
cessful dialysis was delayed by the difficul-
ties in obtaining a useable anticoagulant
and sterile tubing to carry the blood to
the dialyser. In 1945 the first successful
human dialysis was performed by W Kolff
in Holland — his 16th attempted dialysis
in a patient with acute renal failure. His
previous 15 patients had all died, but the
16th patient was successfully treated by
dialysis and went on to long-term sur-
vival. Thereafter dialysis spread across the
world and ushered in a new era in the
treatment of both acute and chronic renal
disease. A major early problem was circu-
latory access for repeated dialysis treat-
ments. The Scribner shunt and subse-
quently the Brescia Cimino fistula as well
as the variations on this have made long-
term repeated circulatory access possible.
Vascular access remains a problem for
many patients requiring long-term dialysis
for chronic renal failure.
DIALYSIS MEMBRANES
Contact of the patient’s blood with a bio-
incompatible membrane such as the cellu-
lose membrane results in an inflammatory
response. The adhesion of platelets and
white cells to the membrane, complement
activation, activation of white cells and
release of a number of inflammatory
cytokines characterise this response. The
synthetic and semisynthetic membranes
minimise this problem. The patients
therefore do not experience the inflamma-
tory response, resulting in a less sympto-
matic dialysis. The reduction in leucocyte
and complement activation which lead to
retarded renal recovery as well as to
adverse effects on other organs such as
the lung is important in the critically ill
patient with acute renal failure where pul-
monary function may be compromised
further. High-flux membranes are
required for continuous renal replacement
therapies. These biocompatible mem-
branes are polysulphones, or acrylonitrile
membranes with high permeability and
high clearances in addition to the other
advantages of increased biocompatibility
( Table I).
M D PASCOE
MB ChB, FCP (SA)
Senior Specialist
and Head  
Division of
Nephrology
Groote Schuur
Hospital and
University of 
Cape Town
Dr Pascoe is
Chairman of the S A
Dialysis and
Transplant Registry, a
member of the SA
Renal Society execu-
tive committee, and
secretary of the SA
Transplant Society. His
special interests are
general clinical
nephrology and renal
transplantation. 
J A HALKETT
MB ChB, FCP (SA)
Senior Specialist
Division of
Nephrology
Groote Schuur
Hospital and
University of 
Cape Town
Dr Halkett is secre-
tary of the SA Dialysis
and Transplant
Registry, a member of
the SA Renal Society
executive committee
and a member of the
SA Transplant Society.
Her special interests
are dialysis and trans-
plantation.
Technology in nephrology
Technology has improved since the first success -
ful dialysis — it is now possible to treat all
patients with acute renal failure.
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Bio-incompatible Bio-compatible
Types Cellulose Acrylonitrile, polysulphone
Cost Cheaper More expensive
Clinical disadvantages Inflammatory response, High permeability 
lower efficiency needs volumetric equipment
Platelet adhesion 
Clinical advantages Adequate for many High efficiency,
no inflammatory response 
Table I. Dialysis membranes
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DIALYSIS FLUIDS
In the early days of haemodialysis
bicarbonate was routinely used as
the anion in dialysis fluid. The
fluid was prepared from powdered
chemicals, which were mixed for
each treatment. A bicarbonate
solution containing the necessary
calcium and magnesium cannot be
stored, as calcium and magnesium
carbonate are insoluble and precip-
itate. These technical problems
have largely been overcome by the
development of two component
systems which separate the bicar-
bonate solution from an ‘acid’
solution containing calcium, mag-
nesium and a small amount of
acetic or lactic acid. The modern
dialysis machine blends these two
components with purified water
just before delivery, avoiding the
problems of precipitation. The
acid component reacts with bicar-
bonate to produce carbon dioxide.
This in turn forms carbonic acid
that lowers the pH of the final
bicarbonate-containing solution,
allowing calcium and magnesium
to remain in solution. Acute renal
failure is often associated with a
more severe degree of acidosis than
occurs with chronic renal failure;
therefore bicarbonate dialysis
should be used for dialysis in acute
renal failure wherever possible.
In the absence of renal function,
the excess non-volatile acid gener-
ated by metabolic processes cannot
be excreted and must be buffered.
Dialysis assists this process by
transferring buffers such as bicar-
bonate, acetate or lactate from the
dialysis solution to the patient’s
circulation. Although acetate-con-
taining dialysate has been the
mainstay of treatment, its use is
associated with nausea and vomit-
ing, as well as haemodynamic
instability and hypotension.
Acetate and lactate must be con-
verted to bicarbonate by the liver,
resulting in a delay in correction of
acidosis. These problems do not
occur with bicarbonate dialysis.
Correction of acidosis is rapid and
patients do not have cardiovascular
instability. Bicarbonate dialysis has
become the standard form of treat-
ment, particularly in the critically
ill patient where severe acidosis
and haemodynamic instability are
common. (Table II).
Peritoneal dialysis fluids containing
lactate as a buffer have been used
widely for continuous haemodialy-
sis. This can be a problem when
the patient has liver dysfunction.
Bicarbonate-containing fluids for
continuous therapy are now com-
mercially available.
Glucose
Although glucose is required in
dialysate fluids in order to com-
pensate for extracorporeal losses,
supraphysiological concentrations
result in hyperglycaemia and
should be avoided, particularly in
the critically ill patient where
hyperglycaemia has been linked to
increased mortality.
DIALYSIS FOR CHRONIC
RENAL FAILURE
The choice of dialysis modality for
patients with chronic renal failure
depends on many factors, includ-
ing availability and logistics, med-
ical factors, and patient prefer-
ences. Patients who develop
chronic, end-stage renal failure and
who receive haemodialysis therapy
usually require dialysis three times
each week. Most patients will
become anuric or severely oliguric
a variable time after commencing
dialysis treatment. Therefore dialy-
sis must substitute for all the
excretory functions of the kidneys,
such as removal of water, elec-
trolytes and metabolic waste prod-
ucts. In this regard dialysis is very
effective, but it is unable to replace
any of the endocrine functions of
the kidney.
The standard dialysis circuit is
illustrated in Fig. 1. The notable
features  are two circuits — a
blood circuit and a fluid circuit —
each guarded by a variety of moni-
tors and alarms. These include, on
the blood side, monitoring of the
pressures in the dialyser and, most
critically, a monitor to detect air in
the circuit. The circuit is fitted
with stop mechanisms to clamp it
off in the event of an air leak. The
dialysate circuit is monitored for
temperature, pressure and conduc-
tivity as well as for the presence of
blood that would indicate a blood
leak. The dialysis treatment is
monitored for safety throughout
the course of treatment, in addition
Acetate Bicarbonate
Relative cost Cheaper More costly
Equipment Simple/basic More complex
Clinical side-effects Nausea Nil
Vomiting
Cramps
Hypotension
Haemodynamic instability
Table II. Dialysis fluids
Patients who develop
chronic end-stage
renal failure and
who receive
haemodialysis ther -
apy usually require
dialysis three times
each week.
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to the usual monitoring of the
patient’s vital signs.
Dialysis technologies have
advanced rapidly over the last years
with the development of biocom-
patible dialysis membranes, volu-
metric dialysis machines, increas-
ing availability of bicarbonate dial-
ysis fluids and improved under-
standing of the assessment of dialy-
sis adequacy. New drugs such as
the vitamin D analogues and
recombinant human erythropoetin
have been major advances in the
management of these patients.
VOLUMETRIC DIALYSIS
A critical factor in the oliguric
patient is fluid management. Fluid
removal must be controlled in such
a manner that sufficient fluid is
removed to allow for oral intake
over the next 2 - 3 days, but at the
same time this has to be done in
such a way as to avoid symptoms
such as cramps and hypotension,
associated with acute volume
depletion. The volumetric dialysis
machine monitors the volume of
dialysate entering the machine and
compares this with the effluent
dialysate volume (Fig. 2). A simple
calculation done in the micro-
processor controlling the equip-
ment then allows the machine to
display the volume removed. It is
a small step from this point to
allow the machine to be set at the
beginning of the treatment to
remove an appropriate volume of
fluid. In the absence of such a
facility the calculations have to be
done by the staff , based on the
published performance data of the
dialyser, which is imprecise and
difficult (Fig. 3).
The combination of volumetric
dialysis and high-flux biocompati-
ble membranes has allowed the
normal diffusive dialysis to be aug-
mented by convective dialysis.
Convective dialysis using these
membranes allows for more effi-
Fig. 1. Layout of basic standard dialysis circuit.
Fig. 2. Layout of dialysis circuit for high-flux dialysis.
Fig. 3. Layout of CVVHD circuit.
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cient dialysis with better removal of
water and electrolytes as well as
much improved clearance of mid-
dle and large molecular weight
substances. There is a major study
(HEMO study)1,2 for which only
preliminary data have been pub-
lished, investigating the value of
high-flux convective dialysis and
different doses of dialysis on the
outcome for the patients. It is dif-
ficult to separate the effects of bio-
compatibility and high-flux dialy-
sis. It has yet to be shown that
these new technologies truly will
improve patient survival and quali-
ty of life. It is, however, highly
probable that these techniques will
have that effect.
The higher performance of these
membranes in terms of larger mol-
ecular weight clearances con-
tributes to a reduction in b2
microglobulin, which is important
in reducing the incidence of dialy-
sis-associated amyloidosis — an
important complication of long-
term dialysis.
DIALYSIS FOR ACUTE
RENAL FAILURE
The role of dialysis in acute renal
failure is to provide support for the
patient until renal recovery occurs
and to prevent life-threatening
complications such as hyper-
kalaemia and fluid overload.
The evolution of new dialysis tech-
niques as well as developments in
the areas of vascular access
catheters, dialysis membranes, flu-
ids and machines have all con-
tributed to improved management
of patients with acute renal failure.
Dialysis modality
The modality of dialysis selected is
determined by the patient’s clinical
profile and by logistic factors. In
the right circumstances, peritoneal
dialysis can be an effective treat-
ment modality and has the advan-
tage of not requiring sophisticated
equipment. However, the majority
of patients with acute renal failure
will not be treated adequately with
peritoneal dialysis and will require
haemodialysis. Intermittent
haemodialysis remains the most
widely used form of treatment for
acute renal failure worldwide. A
major limitation of this type of
renal replacement is its unsuitabili-
ty for certain categories of patients,
notably critically ill patients in
intensive care units, some patients
after cardiac surgery and patients
with raised intracranial pressure.
These patients, particularly those
with severe sepsis and multi-organ
dysfunction, are difficult to treat
with conventional intermittent
haemodialysis because of haemo-
dynamic instability and hypoten-
sion. The development of continu-
ous renal replacement techniques
has been a major development in
the management of these patients.
In 1977 Peter Kramer3 from
Göttingen, Germany, developed
the technique of continuous arteri-
ovenous haemofiltration to dialyse
such patients. Varying forms of
continuous therapy were subse-
quently devised (Table III).4 The
slow and continuous nature of this
form of renal replacement therapy
allows gradual and gentle removal
of fluid, electrolytes, and uraemic
toxins without exacerbating
haemodynamic instability. Other
specific advantages include
improved metabolic control, ability
to provide nutritional support, and
ease with which fluid removal can
be manipulated.
Initially these techniques used sim-
ple arteriovenous blood circuits,
but vascular complications related
to catheterisation of large arteries
led to the development of veno-
venous circuits that required the
inclusion of a blood pump in the
circuit. In South Africa, continu-
ous venovenous haemodialysis
(CVVHD) (Figs 4,5) is the most
widely used form of continuous
therapy.
SCU Slow continuous ultra-filtration
CAVU Continuous arteriovenous ultra-filtration
CAVHD Continuous arteriovenous haemodialysis
CVVHD Continuous venovenous haemodialysis
CVVHF Continuous venovenous haemofiltration
CVVHDF Continuous venovenous haemodiafiltration
Table III. Types of continuous dialysis
Fig. 4. Outpatient on standard inter-
mittent haemodialysis.
Fig. 5. Modern CVVHD equipment.
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Continuous haemofiltration
Haemofiltration is a convective
technique using a transmembrane
pressure gradient to filter plasma
water across a highly permeable
membrane. Small and large mole-
cules are convected across the
membrane with the water (solute
drag effect), thus effecting blood
purification. About 10 - 15 litres
of ultrafiltrate are produced per
day, which must be replaced by a
balanced electrolyte solution
infused into the inflow or outflow
line of the haemofilter.
Continuous haemodialysis
Continuous haemodialysis utilises
the principle of diffusion of solutes
across the dialyser membrane, dri-
ven by a concentration gradient
between the blood and dialysate
fluid compartments. Therefore
fluid transport across the mem-
brane is not a prerequisite for
treatment, but is adjusted accord-
ing to the need for fluid removal.
This can vary from 0 to about 6
liters per day. Of all the slow ther-
apies, continuous haemodialysis
provides the highest daily urea
clearances.
Vascular access
Vascular access in acute renal fail-
ure is achieved by percutaneous
insertion of specially designed dial-
ysis catheters into large veins such
as the internal jugular, femoral or
subclavian veins (Fig. 6). The ideal
catheter is easily inserted, atrau-
matic to the vessel, haemocompati-
ble to minimise thrombosis, and
able to provide adequate blood
flow rates. Modern dialysis
catheters are designed with specific
curves and lengths to suit the site
of insertion. Polyurethane and sili-
cone are regarded as the best mate-
rials for catheters. Silicone
catheters are flexible and soft,
characteristics that decrease the
risk of vascular injury. Some
catheters are designed to soften
once inserted and at body temper-
ature. Semi-rigid catheters should
not be used for protracted periods.
Single- and double-lumen
catheters are available. Single-
lumen catheters require the use of
a single blood path adapter device
to split the blood flow distal to the
catheter using Y tubing. This sys-
tem relies on timers and valves to
push and pull blood from the
blood compartment of the dialyser.
Double-lumen catheters permit the
use of a standard blood circuit and
also minimise recirculation of dial-
ysed blood back into the dialyser,
as occurs with single blood path
devices.
Anticoagulation
Prevention of thrombosis in the
extracorporeal circuit is an impor-
tant aspect of management, partic-
ularly with the continuous forms of
therapy. The new heparins do not
have significant advantages over
the standard unfractionated form,
and in some cases may have disad-
vantages such as prolonged action.
Blood should be drawn proximal to
the heparin infusion port in order
to reflect the clotting profile of the
patient, rather than the extracorpo-
real circuit. Activated clotting time
(ACT) and partial thromboplastin
time (PTT) are monitored. For
intermittent haemodialysis bolus
doses of heparin are used, and it is
possible to perform heparin-free
dialysis provided blood flow rates
are adequate and the dialyser is
frequently flushed with saline.
Prevention of clotting in the dialy-
sis circuit is the main technical
challenge with all forms of slow
continuous dialysis. The require-
ment for prolonged anticoagulation
increases the risk of bleeding. This
has to be balanced against prema-
ture circuit clotting leading to inef-
fective treatment. An initial bolus
of heparin into the ‘arterial’ blood-
line is followed by a constant infu-
sion of heparin. Heparin-free con-
tinuous dialysis is possible, but dif-
ficult, as the dialyser usually clots
within eight hours. Frequent
changes of dialyser and circuit tub-
ing decrease the efficacy of treat-
ment, and add considerably to the
costs.
Hardware
In continuous therapy, the use of a
roller blood pump ensures a con-
stant blood flow rate through the
dialyser. However, as with other
pumped circuits, there is always a
risk of disconnection or air in the
circuit, necessitating the use of air
detectors, venous pressure moni-
tors, alarms and fail-safe devices to
minimise the risk of air embolism
or haemorrhage.
Modern machines for continuous
therapy control fluid removal very
accurately and have decreased the
burden on nursing staff. However,
the technique can still be per-
formed using a basic blood pump
system with two infusion pumps to
control dialysate inflow and out-
flow from the dialyser.
Fig. 6. Dialysis catheters.
Vascular access in
acute renal failure is
achieved by percu -
taneous insertion of
specially designed
dialysis catheters
into large veins
such as the internal
jugular, femoral or
subclavian veins.
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CONCLUSION
Dialysis technology for both acute
and chronic renal failure has
evolved significantly since the first
patient was successfully treated in
1945. It is now possible to treat all
patients with acute renal failure,
even those who are haemodynami-
cally unstable. The availability of
treatment for chronic renal failure
is limited by financial factors to
carefully selected patients in the
public sector and those in the pri-
vate sector with adequate funding.
The improvements in technology
have added to the costs of therapy
and, regrettably, there are many
areas that do not have access to
even the most basic equipment.
The challenges include making the
technology affordable and improv-
ing patient outcome for acute renal
failure, which has an unacceptably
high mortality, as well as for chron-
ic renal failure.
References available on request.
IN A NUTSHELL
Early nephrological referral allows for
uncomplicated transition to dialysis
and improves long-term survival.
Peripheral veins require careful
preservation for future vascular
access in patients with renal disease.
Improved biocompatibility of modern
polysulphone and other membranes
reduces the inflammatory response to
dialysis.
The increased permeability of these
modern membranes improves the
clearance of solutes but does require
volumetrically controlled machines.
Volumetric dialysis equipment allows
the patient’s fluid balance to be very
precisely controlled.
Continuous dialysis therapies for
acute renal failure allow for dialysis
for acutely ill patients who would not
tolerate standard intermittent
haemodialysis.
Continuous dialysis for acute renal
failure allows for intensive nutritional
support and improved and more sta-
ble metabolic and volume control
than standard dialysis.
Continuous dialysis is the treatment of
choice for patients with raised
intracranial pressure.
Bicarbonate-buffered dialysis fluid
provides better acid-base control than
standard acetate dialysis.
Advances in technology are expen-
sive and cost control is of increasing
importance.
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